Skip to content
Back to news
RegulationNovember 16, 2026

FDA Turns Down Summit Lung Cancer Drug Tied to $2B AstraZeneca Deal

FDA Turns Down Summit Lung Cancer Drug Tied to $2B AstraZeneca Deal: PharmoniQ news card

Summit Therapeutics said on Nov. 15, 2026 that the US Food and Drug Administration has declined to approve ivonescimab for a group of patients with advanced lung cancer. The Miami company had asked for approval of the drug with platinum chemotherapy. The request covered non-small cell lung cancer with an EGFR mutation that had already been treated with an EGFR tyrosine kinase inhibitor.

Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF. It was invented by Akeso, Summit's Chinese partner, and was first approved in China in May 2024. No drug of this type is approved in the US, Summit said.

What happened

The FDA sent Summit a complete response letter. According to the company, the agency found that the application did not show substantial evidence of effectiveness because overall survival did not improve by a statistically significant margin.

The filing rested on HARMONi, a global phase 3 trial that compared ivonescimab plus chemotherapy with placebo plus chemotherapy. The study had two primary goals:

  • Progression-free survival: the trial met this goal, Summit said.
  • Overall survival: the main analysis showed a positive trend but missed statistical significance.

The FDA said a progression-free survival benefit alone, without a clear survival gain, did not support a positive balance of benefit and risk, Summit reported. The company pointed to a later, post hoc analysis with a survival hazard ratio of 0.76. That analysis was not part of the trial's main test.

Bloomberg reported that Summit pressed ahead with the filing even though regulators had warned that its data were not strong enough. Co-CEO Robert Duggan said the company was "disappointed for patients and their families."

Why it matters

Bloomberg described ivonescimab as the most advanced dual-action cancer immunotherapy. Investors treat the drug as a test of whether medicines first developed in China can succeed elsewhere, Bloomberg said. Bloomberg added that interest in the drug fuelled a run of licensing deals for comparable Chinese medicines.

The rejected use covers a fairly small group of patients. Summit had put the number of eligible US patients at more than 14,000 a year. One Bloomberg Intelligence analyst had put potential sales at $230 million by 2035.

The bigger bet is still ahead. AstraZeneca has a stake in the outcome. Bloomberg said the drugmaker announced in September that it would put $2 billion into Summit, with the two teaming up on ivonescimab. Should Summit's other studies work, Bloomberg Intelligence sees total sales of $3.8 billion by 2030.

What it means for people in the industry

Summit said the letter does not change its commitment to developing ivonescimab. It cited five positive phase 3 studies between Summit and Akeso. The company is running trials in lung, colorectal, bladder and kidney cancer, including studies that test ivonescimab head to head against Merck's Keytruda.

The company did not announce job cuts or changes to its sites. For teams developing similar drugs, the decision as Summit described it suggests that in this setting a progression-free survival benefit alone may not be enough. Results from Summit's other phase 3 trials are the next ones to watch.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.